Search Results 1931-1940 of 17051 for monoclonal antibody

1. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors - Mayo Clinic

   ... antibodies (for Sub-Part 1C) * Unstable or deteriorating cardiovascular disease within the previous 6 months * Any major surgery within 4 weeks of study ...

2. BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO) - Mayo Clinic

   - Active infection including hepatitis B (known positive HBV/HBsAg result), HCV, or HIV 1/2 (positive HIV) antibodies. - Current or prior use of ...

3. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders - Mayo Clinic

   ... antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. Participation eligibility. Participant eligibility ...

4. A Study to Evaluate the Safety and Tolerability of KTE-X19 in Adults with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - Mayo Clinic

   ... antibodies, BCL-2 inhibitors, and PI3k inhibitors. Subjects must have received ibrutinib for at least 6 months as the last line of therapy prior to ...

5. A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; Known hypersensitivity ...

6. Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis - Mayo Clinic

   Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks of providing informed consent. Female of childbearing potential unwilling to use a ...

7. A study to test whether survodutide helps people with a liver disease called NASH/MASH who have cirrhosis - Mayo Clinic

   Hepatitis B positive (defined as positive HBsAg); Hepatitis C positive (defined as positive HCV antibody and a positive HCV RNA); Serum aspartate ...

8. Researchers ID gene types behind racial disparities in myeloma - Mayo Clinic

   S. Vincent Rajkumar, M.D. · Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry · Multiple ...

9. Expanding Liver Transplant Immunosuppression Minimization Via Everolimus - Mayo Clinic

   ... antibody- mediated rejection episode. 10. Active treatment with any mTOR-inhibitor agent. (everolimus, sirolimus) 11. Contraindication to treatment with ...

10. Individualized Medicine - Mayo Clinic News Network

    (Video animation shows blood stem cells dividing and multiplying. Getty Images). Deep inside the body, a slow-growing cluster of mutated blood cells can ...